Luu Hung N, Lin Hui-Yi, Sørensen Karina Dalsgaard, Ogunwobi Olorunseun O, Kumar Nagi, Chornokur Ganna, Phelan Catherine, Jones Dominique, Kidd LaCreis, Batra Jyotsna, Yamoah Kosj, Berglund Anders, Rounbehler Robert J, Yang Mihi, Lee Sang Haak, Kang Nahyeon, Kim Seung Joon, Park Jong Y, Di Pietro Giuliano
Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA.
Department of Epidemiology and Biostatistics, College of Public Health, University of South Florida, Tampa, FL, USA.
BMC Urol. 2017 Mar 20;17(1):18. doi: 10.1186/s12894-017-0206-6.
Prostate cancer is the most common malignancy among men in the US. Though considerable improvement in the diagnosis of prostate cancer has been achieved in the past decade, predicting disease outcome remains a major clinical challenge. Recent expression profiling studies in prostate cancer suggest microRNAs (miRNAs) may serve as potential biomarkers for prostate cancer risk and disease progression. miRNAs comprise a large family of about 22-nucleotide-long non-protein coding RNAs, regulate gene expression post-transcriptionally and participate in the regulation of numerous cellular processes. In this review, we discuss the current status of miRNA in studies evaluating the disease progression of prostate cancer. The discussion highlights key findings from previous studies, which reported the role of miRNAs in risk and progression of prostate cancer, providing an understanding of the influence of miRNA on prostate cancer. Our review indicates that somewhat consistent results exist between these studies and reports on several prostate cancer related miRNAs. Present promising candidates are miR-1, -21, 106b, 141, -145, -205, -221, and -375, which are the most frequently studied and seem to be the most promising for diagnosis and prognosis for prostate cancer. Nevertheless, the findings from previous studies suggest miRNAs may play an important role in the risk and progression of prostate cancer as promising biomarkers.
前列腺癌是美国男性中最常见的恶性肿瘤。尽管在过去十年里前列腺癌的诊断有了显著改善，但预测疾病预后仍然是一项重大的临床挑战。最近前列腺癌的表达谱研究表明，微小RNA（miRNA）可能作为前列腺癌风险和疾病进展的潜在生物标志物。miRNA由一个大约22个核苷酸长的非蛋白质编码RNA的大家族组成，在转录后调节基因表达，并参与众多细胞过程的调控。在这篇综述中，我们讨论了miRNA在评估前列腺癌疾病进展的研究中的现状。讨论突出了先前研究的关键发现，这些研究报道了miRNA在前列腺癌风险和进展中的作用，有助于了解miRNA对前列腺癌的影响。我们的综述表明，这些研究与关于几种前列腺癌相关miRNA的报告之间存在一定程度的一致结果。目前有前景的候选miRNA是miR-1、-21、106b、141、-145、-205、-221和-375，它们是研究最频繁的，似乎也是前列腺癌诊断和预后最有前景的。然而，先前研究的结果表明，miRNA作为有前景的生物标志物可能在前列腺癌的风险和进展中发挥重要作用。
